Aclaris Therapeutics, Inc. Contracts & Agreements

Amended and Restated Employment Agreement, effective as of July 1, 2023, by and between the Company and Joseph Monahan (Filed With SEC on June 12, 2023)

(a Delaware limited liability company) (a Delaware corporation) Rentable Square Feet First Floor Suite 103 Chesterbrook Corporate Center 701 Lee Road Wayne, Pennsylvania (Filed With SEC on June 1, 2023)

Ninth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 8, 2023)

Amendment No. 1 to Consulting Services Agreement, dated as of March 23, 2023, by and between the Company and Frank Ruffo (Filed With SEC on March 27, 2023)

Eighth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 23, 2023)

Letter Agreement, dated as of November 22, 2022, by and between the Registrant and Neal Walker (Filed With SEC on February 23, 2023)

Separation Agreement and General Release, dated as of December 9, 2022, by and between the Registrant and Frank Ruffo (Filed With SEC on February 23, 2023)

Consulting Agreement, dated as of January 1, 2023, by and between the Registrant and Frank Ruffo (Filed With SEC on February 23, 2023)

Amended and Restated Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Douglas Manion (Filed With SEC on February 23, 2023)

Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Kevin Balthaser (Filed With SEC on February 23, 2023)

Sales Agreement, dated February 23, 2023, by and among Aclaris Therapeutics, Inc., SVB Securities LLC and Cantor Fitzgerald & Co (Filed With SEC on February 23, 2023)

Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell (Filed With SEC on August 3, 2022)

Employment Agreement, dated as of August 1, 2022, by and between the Company and Douglas Manion (Filed With SEC on August 1, 2022)

Sixth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2022)

Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan (Filed With SEC on February 24, 2022)

Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop (Filed With SEC on February 24, 2022)

Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson (Filed With SEC on February 24, 2022)

Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon (Filed With SEC on February 24, 2022)

Seventh Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2022)

Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Neal Walker (Filed With SEC on January 14, 2022)

Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Company and Frank Ruffo (Filed With SEC on January 14, 2022)

Fifth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 5, 2021)

Underwriting Agreement by and among Aclaris Therapeutics, Inc., Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co., dated June 9, 2021 (Filed With SEC on June 11, 2021)

Sales Agreement, dated May 20, 2021, by and among Aclaris Therapeutics, Inc., SVB Leerink LLC and Cantor Fitzgerald & Co (Filed With SEC on May 20, 2021)

Description of Securities (Filed With SEC on February 25, 2021)

Fourth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)

Change in Control Severance Benefit Plan, effective January 1, 2017, as amended by First Amendment to Change in Control Severance Benefit Plan, effective October 2, 2019 (Filed With SEC on February 25, 2021)

Underwriting Agreement by and among Aclaris Therapeutics, Inc., Cantor Fitzgerald & Co. and William Blair & Company, L.L.C., dated January 20, 2021 (Filed With SEC on January 22, 2021)

Purchase Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)

Registration Rights Agreement, dated as of August 13, 2020, by and between the Company and Lincoln Park (Filed With SEC on August 13, 2020)

First Amendment to Clinical and Commercial Supply Agreement, dated as of June 12, 2020, by and between the Registrant and PeroxyChem LLC (Filed With SEC on August 7, 2020)

Second Amendment to Sublease, dated as of April 29, 2020, by and between the Registrant and Auxilium Pharmaceuticals, LLC (Filed With SEC on May 7, 2020)

Loan and Security Agreement, by and among the Company, Confluence Discovery Technologies, Inc. and Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)

Warrant to Purchase Stock, issued to Silicon Valley Bank, dated as of March 30, 2020 (Filed With SEC on March 31, 2020)

Open Market Sale Agreement, dated March 13, 2020, by and between Aclaris Therapeutics, Inc. and Jefferies LLC (Filed With SEC on March 13, 2020)

Description of Securities (Filed With SEC on February 25, 2020)

Second Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2020)

Third Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2020)

Employment Agreement with Frank Ruffo, dated as of September 17, 2015 (Filed With SEC on February 25, 2020)

First Amendment to License and Collaboration Agreement, by and between the Company and Rigel Pharmaceuticals, Inc. dated as of October 15, 2019 (Filed With SEC on October 17, 2019)

Asset Purchase Agreement, by and between the Company and EPI Health, LLC, dated as of October 10, 2019 (Filed With SEC on October 11, 2019)

Form of Performance Stock Option Grant Notice and Stock Option Agreement used in connection with the 2015 Equity Incentive Plan (Filed With SEC on March 18, 2019)

Form of Performance Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the 2015 Equity Incentive Plan (Filed With SEC on March 18, 2019)

Amended & Restated Non-Employee Director Compensation Policy (Filed With SEC on March 18, 2019)

First Amendment to Sublease, dated as of December 13, 2017, by and between the Registrant and Auxilium Pharmaceuticals, LLC (Filed With SEC on March 18, 2019)

Loan and Security Agreement, dated as of October 15, 2018, by and among Oxford Finance LLC, the lenders party thereto, the Registrant, Confluence Discovery Technologies, Inc. and... (Filed With SEC on March 18, 2019)

Asset Purchase Agreement, by and between the Company and Allergan Sales, LLC, dated as of October 15, 2018, as amended on November 30, 2018 (Filed With SEC on December 3, 2018)

Exclusive Patent License Agreement, by and between the Company and Allergan, Inc., dated as of November 30, 2018 (Filed With SEC on December 3, 2018)

Underwriting Agreement by and among Aclaris Therapeutics, Inc., Leerink Partners LLC and Evercore Group L.L.C., dated October 17, 2018 (Filed With SEC on October 18, 2018)

Distribution Agreement, by and between the Registrant and McKesson Specialty Care Distribution Corporation, dated as of October 13, 2017, as amended by Amendment No. 1, dated as... (Filed With SEC on August 3, 2018)

First Amendment to License Agreement, by and between The Trustees of Columbia University in the City of New York and the Registrant, dated as of June 27, 2018 (Filed With SEC on August 3, 2018)

Commercial Supply Manufacturing Services Agreement, by and between the Registrant and James Alexander Corporation, dated as of January 24, 2018 (Filed With SEC on May 8, 2018)

3,260,000 Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on August 11, 2017)

Seventh Amendment to Services Agreement between the Registrant and NST Consulting, LLC, dated as of May 11, 2017 (Filed With SEC on August 8, 2017)

Aclaris Therapeutics, Inc. 2017 Inducement Plan Adopted by the Board of Directors: July 31, 2017 (Filed With SEC on August 1, 2017)

Aclaris Therapeutics, Inc. 2017 Inducement Plan Stock Option Grant Notice (Filed With SEC on August 1, 2017)

Aclaris Therapeutics, Inc. Restricted Stock Unit Grant Notice (2017 Inducement Plan) (Filed With SEC on August 1, 2017)

Employment Agreement with Kamil Ali-Jackson, dated as of September 17, 2015 (Filed With SEC on May 9, 2017)

FOURTH AMENDMENT TO AMENDED AND RESTATED SUBLEASE BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on March 15, 2017)

SIXTH AMENDMENT TO SERVICES AGREEMENT BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on March 15, 2017)

4,000,000 Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on November 18, 2016)

ACLARIS THERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on November 2, 2016)

AMENDMENT TO ASSIGNMENT AGREEMENT (Filed With SEC on June 17, 2016)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 2, 2016)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 2, 2016)

STOCK PURCHASE AGREEMENT (Filed With SEC on May 11, 2016)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on May 11, 2016)

THIRD AMENDMENT TO SERVICES AGREEMENT BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on May 11, 2016)

FOURTH AMENDMENT TO SERVICES AGREEMENT BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on May 11, 2016)

FIFTH AMENDMENT TO SERVICES AGREEMENT BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on May 11, 2016)

THIRD AMENDMENT TO AMENDED AND RESTATED SUBLEASE BETWEEN NST CONSULTING, LLC AND ACLARIS THERAPEUTICS, INC. (Filed With SEC on May 11, 2016)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on November 18, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on November 18, 2015)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on October 1, 2015)

[ ] Aclaris Therapeutics, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on September 25, 2015)

ASSIGNMENT AGREEMENT (Filed With SEC on September 25, 2015)

ACLARIS THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: SEPTEMBER 15, 2015 APPROVED BY THE STOCKHOLDERS: SEPTEMBER 16, 2015 EFFECTIVE DATE: [],... (Filed With SEC on September 25, 2015)

ACLARIS THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on September 25, 2015)

ACLARIS THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) (Filed With SEC on September 25, 2015)

ACLARIS THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on September 25, 2015)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on September 25, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on September 25, 2015)

ACLARIS THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on September 4, 2015)

ACLARIS THERAPEUTICS, INC. AMENDED AND RESTATED 2012 EQUITY COMPENSATION PLAN (Filed With SEC on September 4, 2015)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on September 4, 2015)

CLINICAL AND COMMERCIAL SUPPLY AGREEMENT (Filed With SEC on August 17, 2015)

SERVICES AGREEMENT (Filed With SEC on August 17, 2015)

ASSIGNMENT AGREEMENT (Filed With SEC on August 17, 2015)

FINDERS SERVICES AGREEMENT (Filed With SEC on August 17, 2015)

Category

Industry

Companies

Contracts

Aclaris Therapeutics, Inc. Contracts & Agreements